EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

International Isotopes Inc (INIS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of International Isotopes Inc $0.03, price $0.06, upside -50.0%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US45972C1027

II International Isotopes Inc logo Thin data Sep 23, 2026

International Isotopes Inc

INIS · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0300 · Strongly overvalued (−50%)
!Quality 38/100
!Mixed Growth (revenue 5y +6.9 %/yr)
!Loss-making · -17.6% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (0/12)
!Narrow moat 9/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
Watch International Isotopes Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.1469 $0.0270 Fair Value $0.0300 Feb 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0270 – $0.1469 · the $0.0600 price screens above the $0.0300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow International Isotopes in your weekly email

Every Wednesday you see whether International Isotopes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.

Show more

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

Stock analysis

International Isotopes Inc (INIS) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0300, implying the stock looks roughly 100.0% overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.0100 per share, and 0 of the 3 models we run sit above the $0.0600 price.

Bear case: the DCF Models group reads lowest at $0.0100, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

International Isotopes Inc reported revenue of $13.1M in FY2025 versus $9.7M in FY2021, a compound +7.8%/yr. Reported net income was −$908K in FY2025.

Key figures

Market cap $37.0M · P/S ratio 3.03 · Net margin −6.9% · Return on equity −61.4% · Return on assets (EBIT) −4.3% · Operating margin −55.1% · Revenue (TTM) $12.2M · Revenue growth (YoY) −26.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −50%, INIS screens richer than that median.

Fair Value models

Bear $0.0300 Fair Value $0.0300 Bull $0.0300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth DCF $0.0100 $0.0100 $0.0100 80
FCF DCF $0.0100 $0.0100 $0.0200 79
5Y Revenue Exit n/a n/a $0.0100 69
All 5 models by family
DCF Models
FCF DCF $0.0100 $0.0100 $0.0200 79
5Y Revenue Exit n/a n/a $0.0100 69
10Y Revenue Exit n/a $0.0100 $0.0100 65
Asset-Based
NCAV (Graham) n/a n/a $0.0100 51
Growth DCF
Growth DCF $0.0100 $0.0100 $0.0100 80

Open the full fair value analysis →

Notify me when INIS reaches fair value

Put INIS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 38 · Market factors (momentum, volatility) 26

Profitability 26
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 31
Balance sheet, leverage, solvency risk
Investment 91
Disciplined investing over empire-building
Low Volatility 24
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 39/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Start year 2020 (pandemic). Over 10 years: +6.3% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4.4% (2020) → −7.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+72.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +68.7% a year for the price.

INIS screens 100% overvalued. Compare with Merck KGaA →

Compare International Isotopes Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks

Beats the industry median on 0/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −50% · Below median
Profitability
Return on assets −8% · Bottom 25%
Net margin (TTM) −18% · Bottom 25%
Operating margin (TTM) −55% · Bottom 25%
Growth and dividend
Revenue growth −27% · Bottom 25%
Balance sheet
Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 10.03× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 3.03× · Pricier than median
P/FCF 430.6× · Priciest 25%
PEG 5.59× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)0 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)76 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

International Isotopes Inc · Fair Value
$0.0300 −100%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "International Isotopes Inc Fair Value". https://www.fairvalue-calculator.com/stock/INIS

Frequently asked questions

Is International Isotopes Inc (INIS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0300 versus a price of $0.0600, about −50% upside (overvalued).
What is the fair value of INIS?
Our model-based fair value for International Isotopes Inc is $0.0300 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0600.
What is the quality score of INIS?
International Isotopes Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for International Isotopes Inc (INIS)?
Our model-based price target is the fair value of $0.0300 (as of Sep 23, 2026) from 5 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the International Isotopes Inc stock forecast for 2026?
Our models put fair value at $0.0300, about −50% upside versus a price of $0.0600 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of International Isotopes Inc (INIS)?
International Isotopes Inc reported trailing-twelve-month revenue of about $12.2M (latest available figure, as of Sep 23, 2026).
What growth is priced into International Isotopes Inc (INIS)?
For today's price to be fair in a discounted-cash-flow model, International Isotopes Inc would have to grow free cash flow by +72.7 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.9 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of INIS use?
Our models discount International Isotopes Inc at 10.1 %: a base by market capitalisation (nano), damped by beta 1.17, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For International Isotopes Inc that is +72.7 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has International Isotopes Inc (INIS) delivered so far?
Over the past 5 years revenue at International Isotopes Inc grew +6.9 % a year. The price currently implies +72.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of International Isotopes Inc (INIS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into International Isotopes Inc (+72.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of International Isotopes Inc (INIS)?
The free-cash-flow yield on the price is 0.27 %: that much free cash flow International Isotopes Inc produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of International Isotopes Inc (INIS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For International Isotopes Inc it is $0.0300 per share (as of Sep 23, 2026), against a price of $0.0600. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is International Isotopes Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, INIS trades above its calculated fair value: price $0.0600, fair value $0.0300, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INIS?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0300). For International Isotopes Inc the two are $0.0300 per share apart. That gap is exactly why we show both numbers side by side.
How much is International Isotopes Inc worth?
The market values International Isotopes Inc at about $37.0M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0300 per share.
What is the PEG ratio of INIS?
The PEG ratio of International Isotopes Inc is 5.59 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of International Isotopes Inc (INIS)?
Balance-sheet figures for International Isotopes Inc (as of Sep 23, 2026): return on equity −61.4%, debt of 0.48 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is INIS from its 52-week high?
International Isotopes Inc trades at $0.0600, about 45% below its 52-week high of $0.1100 and 20% above the low of $0.0500 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.
Which stocks are comparable to International Isotopes Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is International Isotopes Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0600, calculated fair value $0.0300 (−50%), Quality Score 38/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INIS calculated?
We run International Isotopes Inc through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. International Isotopes Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of International Isotopes Inc (INIS)?
The closing price on Sep 23, 2026 was $0.0600. Our model-based fair value is $0.0300, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with International Isotopes Inc right now?
The price sits above even our optimistic bull case ($0.0300). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of International Isotopes Inc

How large is the market capitalisation of International Isotopes Inc (INIS)?
The market capitalisation of International Isotopes Inc is $37.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of International Isotopes Inc (INIS)?
The price-to-sales ratio of International Isotopes Inc is 3.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of International Isotopes Inc (INIS)?
The net margin of International Isotopes Inc is −6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of International Isotopes Inc (INIS)?
The return on equity (ROE) of International Isotopes Inc is −61.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of International Isotopes Inc (INIS)?
On an EBIT basis the return on assets of International Isotopes Inc is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of International Isotopes Inc (INIS)?
The operating margin of International Isotopes Inc is −55.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at International Isotopes Inc (INIS)?
Revenue at International Isotopes Inc is growing −26.6% versus a year earlier (3y avg +5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does International Isotopes Inc (INIS) carry?
The net debt of International Isotopes Inc is $237K (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch International Isotopes Inc in the live analysis

One click puts International Isotopes Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.